JAMA Oncology

Papers
(The TQCC of JAMA Oncology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma739
SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China704
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib656
Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer643
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019636
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer554
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer400
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer386
Association of Maximal Extent of Resection of Contrast-Enhanced and Non–Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma305
Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection279
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo267
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer265
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer265
Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer227
Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer216
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer215
Clinical Evidence for Association of Acupuncture and Acupressure With Improved Cancer Pain207
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer206
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer200
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma196
Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic189
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia188
Geriatric Assessment–Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer187
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma185
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer184
Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation175
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer174
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Cli173
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer167
Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019161
Global Retinoblastoma Presentation and Analysis by National Income Level161
Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic158
Update of Incidence, Prevalence, Survival, and Initial Treatment in Patients With Non–Small Cell Lung Cancer in the US157
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer150
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma149
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer146
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia141
External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms140
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers139
Communication With Older Patients With Cancer Using Geriatric Assessment138
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection132
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19132
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue131
COVID-19 in Children With Cancer in New York City130
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma130
Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome130
Efficacy and Safety of Locoregional Radiotherapy With Chemotherapy vs Chemotherapy Alone in De Novo Metastatic Nasopharyngeal Carcinoma130
Evaluation of COVID-19 Mortality and Adverse Outcomes in US Patients With or Without Cancer125
Association of Insurance Status and Racial Disparities With the Detection of Early-Stage Breast Cancer122
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy118
Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer117
Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase116
Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer116
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer115
Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer113
Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma113
Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens112
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma112
Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma111
Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases110
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab108
Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer104
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels103
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer103
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma102
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer102
Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma102
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors102
Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer99
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer98
Efficacy of Savolitinib vs Sunitinib in Patients WithMET-Driven Papillary Renal Cell Carcinoma98
Comparative Effectiveness of Proton vs Photon Therapy as Part of Concurrent Chemoradiotherapy for Locally Advanced Cancer96
Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non–Small Cell Lung Cancer94
Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer94
Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules93
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase I93
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas92
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer91
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer90
Comparison of Multiparametric Magnetic Resonance Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer89
Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer87
Life Expectancy of Adult Survivors of Childhood Cancer Over 3 Decades86
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy86
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers85
Effect of Integrating Machine Learning Mortality Estimates With Behavioral Nudges to Clinicians on Serious Illness Conversations Among Patients With Cancer85
Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer80
Evolution of the Randomized Clinical Trial in the Era of Precision Oncology80
Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference80
Population-Based Prostate Cancer Screening With Magnetic Resonance Imaging or Ultrasonography79
Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer79
Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia79
Telemedicine for Cancer Care in the Time of COVID-1979
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer78
Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival78
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer77
An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries76
Proportion of Never Smokers Among Men and Women With Lung Cancer in 7 US States76
Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients76
Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment76
Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia75
Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer74
Association of Sedentary Behavior With Cancer Mortality in Middle-aged and Older US Adults73
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer73
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer72
Diabetes, Weight Change, and Pancreatic Cancer Risk71
Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma71
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma71
Association Between Breastfeeding and Ovarian Cancer Risk71
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma71
Screening Tools for Identifying Older Adults With Cancer Who May Benefit From a Geriatric Assessment69
Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 205069
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases69
Evaluation of Plasma Microbial Cell-Free DNA Sequencing to Predict Bloodstream Infection in Pediatric Patients With Relapsed or Refractory Cancer68
Validation of a Machine Learning Algorithm to Predict 180-Day Mortality for Outpatients With Cancer67
Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer67
Implementation and Outcomes of Virtual Care Across a Tertiary Cancer Center During COVID-1966
Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers65
Evaluation of Racial/Ethnic Differences in Treatment and Mortality Among Women With Triple-Negative Breast Cancer65
Benign vs Malignant Tumors65
Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates64
Effectiveness of Electroacupuncture or Auricular Acupuncture vs Usual Care for Chronic Musculoskeletal Pain Among Cancer Survivors63
Expansion of Cancer Risk Profile for BRCA1 and BRCA2 Pathogenic Variants63
World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas63
Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer–Specific Mortality Among US Women63
Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer62
Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer61
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma61
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection61
Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk60
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma60
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors60
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of DualERBB2Blockade in Patients WithERBB2-Positive Breast Cancer60
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer59
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer59
Integrated Survival Estimates for Cancer Treatment Delay Among Adults With Cancer During the COVID-19 Pandemic59
Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma58
Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer58
Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease58
Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases58
The Role of Maintenance Strategies in Metastatic Colorectal Cancer56
Assessment of Parking Fees at National Cancer Institute–Designated Cancer Treatment Centers56
Perceived Care and Well-being of Patients With Cancer and Matched Norm Participants in the COVID-19 Crisis56
Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site55
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer55
Effectiveness of High-risk Human Papillomavirus Testing for Cervical Cancer Screening in China55
Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy—A Rare Event55
Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China55
Association of Daily Sitting Time and Leisure-Time Physical Activity With Survival Among US Cancer Survivors55
Attitudes and Factors Associated With COVID-19 Vaccine Hesitancy Among Patients With Breast Cancer55
Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy54
Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 202154
Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer54
Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer53
Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants53
Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype52
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer52
Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set51
Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor–Positive, ERBB2-Negative Advanced Breast Cancer51
Projected Association of Human Papillomavirus Vaccination With Oropharynx Cancer Incidence in the US, 2020-204550
Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases50
Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer50
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia49
Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non–Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features48
Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia48
Incidence and Mortality Risk Spectrum Across Aggressive Variants of Papillary Thyroid Carcinoma48
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer48
Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non–Small Cell Lung Cancer47
Time-Dependent COVID-19 Mortality in Patients With Cancer47
Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations46
HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer46
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients46
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer46
Global Association of COVID-19 Pandemic Measures With Cancer Screening45
Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cance45
Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors45
Tumor Mutation Burden and Cancer Treatment45
Aspirin Use and Risk of Colorectal Cancer Among Older Adults45
Disparities in Cancer Outcomes Due to COVID-19—A Tale of 2 Cities45
Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants44
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-1944
Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II)43
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor43
Olanzapine for the Treatment of Advanced Cancer–Related Chronic Nausea and/or Vomiting43
Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes43
Immune-Mediated Diseases Associated With Cancer Risks43
Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer42
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer42
Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer42
Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma42
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib41
Association of COVID-19 mRNA Vaccine With Ipsilateral Axillary Lymph Node Reactivity on Imaging41
Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe41
COVID-19 and Cancer41
Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia41
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis40
Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non–Small Cell Lung Cancer and Poor Performance Status40
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer40
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma39
Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan39
Multi-institutional Analysis of Prognostic Factors and Outcomes After Hypofractionated Stereotactic Radiotherapy to the Resection Cavity in Patients With Brain Metastases39
Association of Intratumoral Microbiota With Prognosis in Patients With Nasopharyngeal Carcinoma From 2 Hospitals in China39
Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer38
Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment38
Frequency of and Factors Associated With Nonmedical Opioid Use Behavior Among Patients With Cancer Receiving Opioids for Cancer Pain38
Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant38
Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer38
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant38
Effects of Exercise on Cardiorespiratory Fitness and Biochemical Progression in Men With Localized Prostate Cancer Under Active Surveillance38
Risk of Pancreatic Cancer Among Individuals With Pathogenic Variants in the ATM Gene38
Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease38
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma38
Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination38
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases38
Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer37
Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA37
Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer37
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer36
Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome36
Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor–Positive, Node-Positive Breast Cancer36
Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer36
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma36
Palliative Care for Patients With Cancer in the COVID-19 Era36
Comparison of Survival After Transoral Robotic Surgery vs Nonrobotic Surgery in Patients With Early-Stage Oropharyngeal Squamous Cell Carcinoma36
Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy35
Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation–Positive Non–Small Cell Lung Cancer35
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer35
Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment35
Association Between Surgical Technical Skill and Long-term Survival for Colon Cancer35
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer35
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma35
Rethinking Clinical Trials Reform During the COVID-19 Pandemic34
Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial34
Practical Considerations for the Use of Circulating Tumor DNA in the Treatment of Patients With Cancer34
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma34
Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy34
Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants34
Treatment Selection in First-line Metastatic Renal Cell Carcinoma—The Contemporary Treatment Paradigm in the Age of Combination Therapy34
Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia34
Screening for COVID-19 in Asymptomatic Patients With Cancer in a Hospital in the United Arab Emirates34
Cost-effectiveness of Leveraging Social Determinants of Health to Improve Breast, Cervical, and Colorectal Cancer Screening33
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System33
Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials33
Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma33
Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas33
Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database33
Trends in Cancer Mortality Among Black Individuals in the US From 1999 to 201932
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer32
Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma32
Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer32
Reproductive Outcomes After Breast Cancer in Women With vs Without Fertility Preservation31
0.051546812057495